--- title: "TransThera Raises HK$282 Million via H-Share Placing to Fund Cancer Drug Push" type: "News" locale: "en" url: "https://longbridge.com/en/news/283489861.md" description: "TransThera Sciences (Nanjing), Inc. has raised approximately HK$282 million through the placement of 5,085,000 new H shares at HK$57.03 each. The funds will primarily support research and development, with 57% allocated to advancing its oncology drug Tinengotinib, 33% for manufacturing and commercialization in China, and 10% for working capital. This move aims to broaden the investor base while modestly diluting existing shareholders. TransThera focuses on innovative oncology therapies and is also developing pipeline candidates like TT-00973." datetime: "2026-04-21T11:15:53.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/283489861.md) - [en](https://longbridge.com/en/news/283489861.md) - [zh-HK](https://longbridge.com/zh-HK/news/283489861.md) --- # TransThera Raises HK$282 Million via H-Share Placing to Fund Cancer Drug Push ### Claim 30% Off TipRanks - Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions - Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks An announcement from TransThera Sciences (Nanjing). Inc. ( (HK:2617) ) is now available. TransThera Sciences (Nanjing), Inc. has completed a placing of 5,085,000 new H shares under its general mandate, raising gross proceeds of about HK$290 million at HK$57.03 per share from at least six professional and institutional investors who remain below the substantial shareholder threshold. The new shares represent roughly 1.65% of the enlarged H share capital and 1.26% of total issued shares, modestly diluting existing holders while broadening the investor base. Net proceeds of approximately HK$282.15 million will be directed mainly to research and development, with about 57% earmarked for advancing clinical programs for its core oncology drug Tinengotinib across multiple cancer indications and for TT-00973. Around 33% of the funds will support manufacturing and commercialization of Tinengotinib in China, including building commercial teams and marketing, while the remaining 10% is allocated to working capital and general corporate purposes, strengthening TransThera’s funding for near- to mid-term growth initiatives. **More about TransThera Sciences (Nanjing). Inc.** TransThera Sciences (Nanjing), Inc. is a biopharmaceutical company based in the People’s Republic of China, focused on developing and commercializing innovative oncology therapies. Its core product, Tinengotinib, targets multiple cancer indications, and the company is also advancing pipeline candidates such as TT-00973 for further clinical development and potential market expansion. **Average Trading Volume:** 2,482,081 **Technical Sentiment Signal:** Strong Sell **Current Market Cap:** HK$21.35B Find detailed analytics on 2617 stock on TipRanks’ Stock Analysis page. ### Related Stocks - [02617.HK](https://longbridge.com/en/quote/02617.HK.md) - [513120.CN](https://longbridge.com/en/quote/513120.CN.md) - [520880.CN](https://longbridge.com/en/quote/520880.CN.md) - [159506.CN](https://longbridge.com/en/quote/159506.CN.md) - [159992.CN](https://longbridge.com/en/quote/159992.CN.md) - [520500.CN](https://longbridge.com/en/quote/520500.CN.md) - [159892.CN](https://longbridge.com/en/quote/159892.CN.md) - [520690.CN](https://longbridge.com/en/quote/520690.CN.md) - [159316.CN](https://longbridge.com/en/quote/159316.CN.md) - [159570.CN](https://longbridge.com/en/quote/159570.CN.md) ## Related News & Research - [GenFleet Asserts Independent IP for Pan RAS Inhibitor GFH276 Amid Sector Dispute](https://longbridge.com/en/news/284312081.md) - [Grand Pharmaceutical Moves to Adopt New Bye-Laws Aligned With HK Paperless Regime](https://longbridge.com/en/news/284576690.md) - [05:22 ETEnergenesis Biomedical to Present Clinical Application of ENERGI-F703DFU for Diabetic Foot Ulcers at EWMA 2026](https://longbridge.com/en/news/284533464.md) - [CSPC Innovation Posts Strong Revenue Growth but Wider Losses in Q1 2026](https://longbridge.com/en/news/284213122.md) - [ZAWYA: Emirates Drug Establishment approves first nasal epinephrine spray as alternative to injections for severe allergic reaction](https://longbridge.com/en/news/284603051.md)